ImmVirX receives $6.27 million R&D Tax Incentive Cash Offset from ATO
Melbourne, Australia 13 January 2026 – ImmVirX Pty Limited (“ImmVirX”), a clinical-stage life sciences company developing next-generation, receptor-targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $6,274,594 Research and Development (R&D) Tax Incentive refund from the Australian Taxation Office (ATO). This amount […]
